Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HOPO 14-1
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SRI’s Radioactive Contamination Treatment Is Now in Its First-In-Human Trial
Details : HOPO 14-1 (3,4,3-Li(1,2-hopo) is a novel orally administered experimental drug, designed to act as a defence against radioactive threats and is being investigated to treat radioactive contamination in the body.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 15, 2023
Lead Product(s) : HOPO 14-1
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HOPO 14-1
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Single Oral Doses of HOPO 14-1 Evaluating Safety, Tolerability, Pharmacokinetics
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 29, 2022
Lead Product(s) : HOPO 14-1
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
SRI International Announces Collaboration Agreement with Janssen
Details : Under the terms of the agreement, the organizations and their scientists will leverage SRI’s SynFini™ platform, an artificial intelligence (Al)-guided, automated synthetic- chemistry system for small molecule drug discovery.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 01, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : VEE VLP Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : US Army Medical Research Institute of Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
December 17, 2018
Lead Product(s) : VEE VLP Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : US Army Medical Research Institute of Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lidocaine
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : TKL Research, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Standard TDS Irritation Study: Trained Skin Grader vs. Digital Imaging
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 01, 2016
Lead Product(s) : Lidocaine
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : TKL Research, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable